Allied Biotech Corporation
Allied Biotech Corporation manufactures and sells carotenoids worldwide. Its products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharm… Read more
Allied Biotech Corporation - Asset Resilience Ratio
Allied Biotech Corporation (1780) has an Asset Resilience Ratio of 2.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Allied Biotech Corporation's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Allied Biotech Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$50.95 Million | 2.22% |
| Total Liquid Assets | NT$50.95 Million | 2.22% |
Asset Resilience Insights
- Limited Liquidity: Allied Biotech Corporation maintains only 2.22% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Allied Biotech Corporation Industry Peers by Asset Resilience Ratio
Compare Allied Biotech Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Allied Biotech Corporation (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Allied Biotech Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.39% | NT$8.91 Million | NT$2.26 Billion | -4.72pp |
| 2023-12-31 | 5.11% | NT$106.28 Million | NT$2.08 Billion | -0.08pp |
| 2022-12-31 | 5.19% | NT$113.25 Million | NT$2.18 Billion | -10.66pp |
| 2021-12-31 | 15.84% | NT$386.82 Million | NT$2.44 Billion | +4.24pp |
| 2020-12-31 | 11.60% | NT$262.30 Million | NT$2.26 Billion | -6.15pp |
| 2019-12-31 | 17.75% | NT$345.73 Million | NT$1.95 Billion | -- |